about
Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathyThe relationship between proteinuria and coronary risk: a systematic review and meta-analysisAn update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006.Prevalence of chronic kidney disease in Thai adults: a national health survey.TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy.Combined effect of body mass index and metabolic status on the risk of prevalent and incident chronic kidney disease: a systematic review and meta-analysis.HMGB1 is activated in type 2 diabetes mellitus patients and in mesangial cells in response to high glucoseEffects of p53 on aldosterone-induced mesangial cell apoptosis in vivo and in vitroBiomarkers and health-related quality of life in end-stage renal disease: a systematic review.The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study.Health-related quality of life in hemodialysis patients: an Iranian multi-center study.Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy.Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2)The role of sympathetic nervous activity in renal injury and end-stage renal disease.Renal diseases in haemophilic patients: pathogenesis and clinical management.Role of Toll-like receptors in diabetic nephropathy.The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules.Chronic kidney disease in Asia: Protocol for a collaborative overview.Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].Toll-like receptor 2 agonist exacerbates renal injury in diabetic mice.Renal function in adult Jamaicans with homozygous sickle cell disease.SOCS2 overexpression alleviates diabetic nephropathy in rats by inhibiting the TLR4/NF-κB pathway.Cathepsin D protects renal tubular cells from damage induced by high glucose independent of its enzymatic activity.Psychiatric disorders in patients with end-stage renal disease.Metabolic abnormalities, but not obesity, contribute to the mildly reduced eGFR in middle-aged and elderly Chinese.Diphlorethohydroxycarmalol Attenuates Methylglyoxal-Induced Oxidative Stress and Advanced Glycation End Product Formation in Human Kidney Cells.
P2860
Q28258849-E58FF389-BA05-4814-A7CD-3FF1F1D7E7CFQ33378672-AAC8B132-B578-4EAF-8178-13061C71A9E8Q33509778-705D5E17-C32D-41C3-B412-1A2B6B00ECEEQ33514125-43703AE2-8709-4228-A0E6-F4BC64862E32Q33633050-241C1D43-F4BD-4898-942E-6E6029CD43DFQ33829253-38561206-B3CC-4AA7-9F12-F0FC5E5ED35BQ35919099-AD11303A-53C0-4986-A05D-F4D01A190B9EQ36931242-FE6B83BD-AAA1-4DC3-955F-549737DD37AAQ36947338-ABA86238-3919-41E3-AB78-E13F718FB25CQ36980849-5CBE37F6-0B4A-45AD-B212-DB8721EF6CA7Q37347847-33C3A016-09F6-493A-95B0-F15AC65B2333Q37587328-587D0988-CF2C-47E5-A529-828D23F655E0Q37713054-E57C2336-654C-4224-87AA-3006F8F408CEQ37719241-52248371-27E1-47A2-B94C-5F6BDAA69C9AQ38104767-495742B5-EC98-4B00-8D65-1E28010C46AEQ38184614-42937B1B-DA1D-47CF-B5B4-07466777022CQ39168114-352C85DA-7F76-48E6-9AD2-C7691020FAB3Q39760502-95265224-DAC3-4E84-8130-F95E3E88D093Q41339341-6A0D792A-2B84-408C-8643-CF5FFCE62326Q42316686-00155202-6F9A-42A5-B182-2F50219CD989Q46045843-C1BC37BE-8D82-4B85-994C-EF286DDF48B2Q47141766-463F9955-8EC8-4373-A31A-47171E7BCD29Q47193848-82BC94B7-D030-4532-BA5B-982D1002A300Q48005114-B539547C-5952-49A6-8996-83C401EDA372Q51317747-24064B96-7896-4ECC-9F9D-9CC5CE5802E1Q54949436-F2C79F09-EDE7-4F37-AC89-183B621F9409
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Chronic kidney disease in the general population.
@ast
Chronic kidney disease in the general population.
@en
type
label
Chronic kidney disease in the general population.
@ast
Chronic kidney disease in the general population.
@en
prefLabel
Chronic kidney disease in the general population.
@ast
Chronic kidney disease in the general population.
@en
P2093
P1476
Chronic kidney disease in the general population.
@en
P2093
P356
10.1053/J.ACKD.2004.10.009
P577
2005-01-01T00:00:00Z